Expanding Our Understanding of dd-cfDNA in Providing Lung Transplant Personalized Care
At their industry symposium at ISHLT2025, Natera provided a brief history of dd-cfDNA in lung transplantation rejection monitoring, highlighting the power of the negative to rule out rejection.
Understandably, elevated dd-cfDNA% results are more common in lung than other solid organ transplant due to the nature of detecting tissue damage or injury. Infection is a common cause for elevated results in lung, but elevated Prospera Lung tests may also lead to important clinical insights for complex patients. The session also explores clinical case studies where elevated Prospera results led to key clinical insights for patients to better their care.
Through the support of Natera, this session is now available for you to view on demand.
The content of this recording was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.